Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies
Background The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation is no longer an “elusive” target, having become an important therapeutic target in non-small cell lung cancer (NSCLC). The approvals of sotorasib and adagrasib have significantly altered the second-line treatment algorithm. This systemat...